18 results on '"Ciepluch H."'
Search Results
2. SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naive (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
- Author
-
Tam C.S., Giannopoulos K., Jurczak W., Simkovic M., Shadman M., Osterborg A., Laurenti L., Walker P., Opat S., Chan H., Ciepluch H., Greil R., Tani M., Trneny M., Brander D.M., Flinn I.W., Grosicki S., Verner E., Brown J.R., Kahl B.S., Ghia P., Tian T., Marimpietri C., Paik J.C., Cohen A., Huang J., Robak T., Hillmen P., Tam C.S., Giannopoulos K., Jurczak W., Simkovic M., Shadman M., Osterborg A., Laurenti L., Walker P., Opat S., Chan H., Ciepluch H., Greil R., Tani M., Trneny M., Brander D.M., Flinn I.W., Grosicki S., Verner E., Brown J.R., Kahl B.S., Ghia P., Tian T., Marimpietri C., Paik J.C., Cohen A., Huang J., Robak T., and Hillmen P.
- Abstract
Background: Zanubrutinib (zanu) is a selective next-generation Bruton tyrosine kinase (BTK) inhibitor designed to have high specificity for BTK and minimize off-target effects (Guo, J Med Chem 2019;62:7923-40). In a phase 1/2 study, zanu demonstrated complete and sustained BTK occupancy in both peripheral blood mononuclear cells and lymph nodes and was associated with durable clinical responses in patients (pts) with CLL/SLL (Tam, Blood 2019;134:851-9). Here, we present interim results for the phase 3 SEQUOIA (BGB-3111-304; NCT03336333) trial, which evaluated the efficacy and safety of zanu vs BR in TN pts with CLL/SLL. Method(s): SEQUOIA is an open-label, global phase 3 study that randomized TN pts with CLL/SLL without del(17p) to receive zanu 160 mg twice daily until progressive disease or unacceptable toxicity, or bendamustine 90 mg/m 2 on day 1 and 2 and rituximab 375 mg/m 2 in cycle 1, 500 mg/m 2 in cycles 2-6 for 6 x 28-day cycles. Adult pts with CLL/SLL who met International Workshop on CLL (iwCLL) criteria for treatment (Hallek, Blood 2008;111:5446-56) were eligible if they were either >=65 y or unsuitable for treatment with fludarabine, cyclophosphamide and rituximab. Central verification of del(17p) status by fluorescence in situ hybridization was required. Pts were stratified by age (<65 y vs >=65 y), Binet Stage (C vs A/B), IGHV mutational status, and geographic region. The primary endpoint was independent...Copyright © 2021 American Society of Hematology
- Published
- 2022
3. SEQUOIA : Results of a Phase 3 Randomised Study of Zanubrutinib versus Bendamustine + Rituximab in Patients with Treatment-Naive Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma.
- Author
-
Munir T., Giannopoulos K., Jurczak W., Simkovic M., Shadman M., Osterborg A., Laurenti L., Walker P., Opat S., Chan H., Ciepluch H., Greil R., Tani M., Trneny M., Brander D.M., Flinn I.W., Grosicki S., Verner E., Kahl B.S., Ghia P., Li J., Tian T., Zhou L., Marimpietri C., Paik J.C., Cohen A., Huang J., Brown J.R., Robak T., Tam C.S., Munir T., Giannopoulos K., Jurczak W., Simkovic M., Shadman M., Osterborg A., Laurenti L., Walker P., Opat S., Chan H., Ciepluch H., Greil R., Tani M., Trneny M., Brander D.M., Flinn I.W., Grosicki S., Verner E., Kahl B.S., Ghia P., Li J., Tian T., Zhou L., Marimpietri C., Paik J.C., Cohen A., Huang J., Brown J.R., Robak T., and Tam C.S.
- Abstract
Zanubrutinib (zanu) is a selective nextgeneration Bruton tyrosine kinase (BTK) inhibitor designed to have high specificity for BTK and minimal off-target effects. SEQUOIA (NCT03336333) is an open-label, global phase 3 study that randomised treatment naive (TN) patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) without del(17p) to receive zanu 160 mg twice daily until progressive disease or unacceptable toxicity, or bendamustine 90 mg/m2 on day 1 and 2 and rituximab 375 mg/m2 in cycle 1, 500 mg/m2 in cycles 2-6 for 6 x 28-day cycles (BR). Adult patients who met International Workshop on CLL (iwCLL) criteria for treatment were eligible if they were >= 65 years or unsuitable for treatment with fludarabine, cyclophosphamide and rituximab. Central verification of del(17p) status by fluorescence in situ hybridisation was required. Patients were stratified by age (<65 years vs. >=65 years), Binet Stage (C vs. A/B), immunoglobulin heavy chain gene (IGHV) mutational status and geographical region. The primary end-point was independent review committee (IRC)-assessed progression-free survival (PFS). Secondary end-points included PFS by investigator assessment (INV), overall response rate (ORR; by IRC and INV), overall survival (OS) and safety. Responses for CLL and SLL were assessed per modified iwCLL criteria and Lugano criteria respectively. Adverse events (AEs) were recorded until disease progression. From 31 Oct 2017-22 Jul 2019, 479 patients without del(17p) were randomised to zanu ( n = 241) and BR ( n = 238). Treatment groups were well balanced for demographical and disease characteristics (zanu vs. BR): median age, 70.0 years vs. 70.0 years; unmutated IGHV, 53.4% (125/234) vs. 52.4% (121/231); and del(11q), 17.8% vs. 19.3%. At median followup (26.2 months), PFS was significantly prolonged with zanu versus BR as assessed by IRC (hazard ratio [HR] 0.42, 95% CI 0.28-0.63, 2-sided p < 0.0001), and INV (HR 0.42, 95% CI 0.27-0.66, 2-sided p = 0
- Published
- 2022
4. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
- Author
-
Tam C.S., Brown J.R., Kahl B.S., Ghia P., Giannopoulos K., Jurczak W., Simkovic M., Shadman M., Osterborg A., Laurenti L., Walker P., Opat S., Chan H., Ciepluch H., Greil R., Tani M., Trneny M., Brander D.M., Flinn I.W., Grosicki S., Verner E., Tedeschi A., Li J., Tian T., Zhou L., Marimpietri C., Paik J.C., Cohen A., Huang J., Robak T., Hillmen P., Tam C.S., Brown J.R., Kahl B.S., Ghia P., Giannopoulos K., Jurczak W., Simkovic M., Shadman M., Osterborg A., Laurenti L., Walker P., Opat S., Chan H., Ciepluch H., Greil R., Tani M., Trneny M., Brander D.M., Flinn I.W., Grosicki S., Verner E., Tedeschi A., Li J., Tian T., Zhou L., Marimpietri C., Paik J.C., Cohen A., Huang J., Robak T., and Hillmen P.
- Abstract
Background: Zanubrutinib is a next-generation, selective Bruton tyrosine kinase inhibitor with efficacy in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). We compared zanubrutinib with bendamustine-rituximab to determine its effectiveness as frontline therapy in patients with CLL or SLL. Method(s): We conducted an open-label, multicentre, phase 3 study at 153 academic or community hospitals in 14 countries and regions. Eligible patients had untreated CLL or SLL requiring treatment as per International Workshop on CLL criteria; were aged 65 years or older, or 18 years or older and had comorbidities; and had an Eastern Cooperative Oncology Group performance status score of 0-2. A central interactive web response system randomly assigned patients without del(17)(p13.1) to zanubrutinib (group A) or bendamustine-rituximab (group B) by sequential block method (permutated blocks with a random block size of four). Patients with del(17)(p13.1) were enrolled in group C and received zanubrutinib. Zanubrutinib was administered orally at 160 mg twice per day (28-day cycles); bendamustine at 90 mg/m2 of body surface area on days 1 and 2 for six cycles plus rituximab at 375 mg/m2 of body surface area the day before or on day 1 of cycle 1, and 500 mg/m2 of body surface area on day 1 of cycles 2-6, were administered intravenously. The primary endpoint was progression-free survival per independent review committee in the intention-to-treat population in groups A and B, with minimum two-sided alpha of 0.05 for superiority. Safety was analysed in all patients who received at least one dose of study treatment. The study is registered with ClinicalTrials.gov, NCT03336333, and is closed to recruitment. Finding(s): Between Oct 31, 2017, and July 22, 2019, 590 patients were enrolled; patients without del(17)(p13.1) were randomly assigned to zanubrutinib (group A; n=241) or bendamustine-rituximab (group B; n=238). At median follow-up of 26.2 months (IQR 23.7
- Published
- 2022
5. CLL-137 SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine + Rituximab (BR) in Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/ SLL)
- Author
-
Kahl, B. S., Giannopoulos, K., Jurczak, W., Simkovic, M., Shadman, M., Osterborg, A., Laurenti, Luca, Walker, P., Opat, S., Chan, H., Ciepluch, H., Greil, R., Tani, M., Trneny, M., Brander, D. M., Flinn, I. W., Grosicki, S., Verner, E., Brown, J. R., Ghia, P., Li, J., Tian, T., Zhou, L., Marimpietri, C., Paik, J. C., Cohen, A., Robak, T., Hillmen, P., Tam, C. S., Laurenti L. (ORCID:0000-0002-8327-1396), Kahl, B. S., Giannopoulos, K., Jurczak, W., Simkovic, M., Shadman, M., Osterborg, A., Laurenti, Luca, Walker, P., Opat, S., Chan, H., Ciepluch, H., Greil, R., Tani, M., Trneny, M., Brander, D. M., Flinn, I. W., Grosicki, S., Verner, E., Brown, J. R., Ghia, P., Li, J., Tian, T., Zhou, L., Marimpietri, C., Paik, J. C., Cohen, A., Robak, T., Hillmen, P., Tam, C. S., and Laurenti L. (ORCID:0000-0002-8327-1396)
- Abstract
Context: The Bruton tyrosine kinase (BTK) inhibitor, zanubrutinib, was designed for high BTK specificity and minimal toxicity. SEQUOIA (NCT03336333) is a global, open-label, randomized phase 3 study in treatment-naïve patients with CLL/SLL without del(17p) who were unsuitable for fludarabine/cyclophosphamide/rituximab. Design: Patients were randomized to receive zanubrutinib (160 mg twice daily) or bendamustine (day 1-2: 90 mg/m2) and rituximab (cycle 1: 375 mg/m2; cycles 2-6: 500 mg/m2); stratification factors were age (<65 years vs ≥65 years), Binet Stage, IGHV mutation, and geographic region. Main Outcome Measures: Primary endpoint was an independent review committee (IRC)-assessed progression-free survival (PFS). Secondary endpoints included investigator-assessed (INV) PFS, overall response rate (ORR), overall survival (OS), and safety. Results: From October 31, 2017, to July 22, 2019, 479 patients were enrolled (zanubrutinib=241; BR=238). Baseline characteristics (zanubrutinib vs BR): median age, 70.0 years versus 70.0 years; unmutated IGHV, 53.4% versus 52.4%; del(11q), 17.8% versus 19.3%. With median follow-up of 26.2 months, PFS was significantly prolonged with zanubrutinib by IRC (HR 0.42; 2-sided P<.0001) and INV (HR 0.42; 2-sided P=.0001). Zanubrutinib treatment benefit occurred across age, Binet stage, bulky disease, del(11q) status, and unmutated IGHV (HR 0.24; 2-sided P<.0001), but not mutated IGHV (HR 0.67; 2-sided P=.1858). For zanubrutinib versus BR, 24-month PFS-IRC=85.5% versus 69.5%; ORR-IRC=94.6% versus 85.3%; complete response rate=6.6% versus 15.1%; ORR-INV=97.5% versus 88.7%; and 24-month OS=94.3% versus 94.6%. Select adverse event (AE) rates (zanubrutinib vs BR): atrial fibrillation (3.3% vs 2.6%), bleeding (45.0% vs 11.0%), hypertension (14.2% vs 10.6%), infection (62.1% vs 55.9%), and neutropenia (15.8% vs 56.8%). Treatment discontinuation due to AEs (zanubrutinib vs BR)=20 patients (8.3%) versus 31 patients (13.7%); AEs leading
- Published
- 2022
6. Zanubrutinib monotherapy for patients with treatment naive chronic lymphocytic leukemia and 17p deletion.
- Author
-
Tam C.S., Robak T., Ghia P., Kahl B.S., Walker P., Janowski W., Simpson D., Shadman M., Ganly P.S., Laurenti L., Opat S., Tani M., Ciepluch H., Verner E., Simkovic M., Osterborg A., Trneny M., Tedeschi A., Paik J.C., Kuwahara S.B., Feng S., Ramakrishnan V., Cohen A., Huang J., Hillmen P., Brown J.R., Tam C.S., Robak T., Ghia P., Kahl B.S., Walker P., Janowski W., Simpson D., Shadman M., Ganly P.S., Laurenti L., Opat S., Tani M., Ciepluch H., Verner E., Simkovic M., Osterborg A., Trneny M., Tedeschi A., Paik J.C., Kuwahara S.B., Feng S., Ramakrishnan V., Cohen A., Huang J., Hillmen P., and Brown J.R.
- Abstract
Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma whose tumors carry deletion of chromosome 17p13.1 [del(17p)] have an unfavorable prognosis and respond poorly to standard chemoimmunotherapy. Zanubrutinib is a selective next-generation Bruton tyrosine kinase inhibitor. We evaluated the safety and efficacy of zanubrutinib 160 mg twice daily in treatment-naive patients with del(17p) disease enrolled in a dedicated, nonrandomized cohort (Arm C) of the phase 3 SEQUOIA trial. A total of 109 patients (median age, 70 years; range, 42 - 86) with centrally confirmed del(17p) were enrolled and treated. After a median of 18.2 months (range, 5.0 - 26.3), seven patients had discontinued study treatment due to progressive disease, four due to an adverse event, and one due to withdrawal of consent. The overall response rate was 94.5% with 3.7% of patients achieving complete response with or without incomplete hematologic recovery. The estimated 18-month progression-free survival rate was 88.6% (95% CI, 79.0 - 94.0) and the estimated 18-month overall survival rate was 95.1% (95% CI, 88.4 - 98.0). Most common all-grade adverse events included contusion (20.2%), upper respiratory tract infection (19.3%), neutropenia/neutrophil count decreased (17.4%), and diarrhea (16.5%). Grade >= 3 adverse events were reported in 53 patients (48.6%), most commonly neutropenia (12.9%) and pneumonia (3.7%). An adverse event of atrial fibrillation was reported in three patients (2.8%). Zanubrutinib was active and well tolerated in this large, prospectively enrolled treatment cohort of previously untreated patients with del(17p) chronic lymphocytic leukemia/small lymphocytic lymphoma. This trial was registered at ClinicalTrials.gov as #NCT03336333.
- Published
- 2021
7. Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion
- Author
-
Tam, C. S., Robak, T., Ghia, P., Kahl, B. S., Walker, P., Janowski, W., Simpson, D., Shadman, M., Ganly, P. S., Laurenti, Luca, Opat, S., Tani, M., Ciepluch, H., Verner, E., Simkovic, M., Osterborg, A., Trneny, M., Tedeschi, Alessandra, Paik, J. C., Kuwahara, S. B., Feng, S., Ramakrishnan, V., Cohen, A., Huang, J., Hillmen, P., Brown, J. R., Laurenti L. (ORCID:0000-0002-8327-1396), Tedeschi A., Tam, C. S., Robak, T., Ghia, P., Kahl, B. S., Walker, P., Janowski, W., Simpson, D., Shadman, M., Ganly, P. S., Laurenti, Luca, Opat, S., Tani, M., Ciepluch, H., Verner, E., Simkovic, M., Osterborg, A., Trneny, M., Tedeschi, Alessandra, Paik, J. C., Kuwahara, S. B., Feng, S., Ramakrishnan, V., Cohen, A., Huang, J., Hillmen, P., Brown, J. R., Laurenti L. (ORCID:0000-0002-8327-1396), and Tedeschi A.
- Abstract
Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma whose tumors carry deletion of chromosome 17p13.1 [del(17p)] have an unfavorable prognosis and respond poorly to standard chemoimmunotherapy. Zanubrutinib is a selective next-generation Bruton tyrosine kinase inhibitor. We evaluated the safety and efficacy of zanubrutinib 160 mg twice daily in treatment-naïve patients with del(17p) disease enrolled in a dedicated, nonrandomized cohort (Arm C) of the phase III SEQUOIA trial. A total of 109 patients (median age, 70 years; range, 42–86) with centrally confirmed del(17p) were enrolled and treated. After a median of 18.2 months (range, 5.0–26.3), seven patients had discontinued study treatment due to progressive disease, four due to an adverse event, and one due to withdrawal of consent. The overall response rate was 94.5% with 3.7% of patients achieving complete response with or without incomplete hematologic recovery. The estimated 18-month progression-free survival rate was 88.6% (95% CI: 79.0–94.0) and the estimated 18-month overall survival rate was 95.1% (95% CI: 88.4–98.0). Most common all-grade adverse events included contusion (20.2%), upper respiratory tract infection (19.3%), neutropenia/neutrophil count decreased (17.4%), and diarrhea (16.5%). Grade ≥ 3 adverse events were reported in 53 patients (48.6%), most commonly neutropenia (12.9%) and pneumonia (3.7%). An adverse event of atrial fibrillation was reported in three patients (2.8%). Zanubrutinib was active and well tolerated in this large, prospectively enrolled treatment cohort of previously untreated patients with del(17p) chronic lymphocytic leukemia/small lymphocytic lymphoma. This trial was registered as clinicaltrials.gov Identifier: NCT03336333.
- Published
- 2021
8. Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion.
- Author
-
Tam, CS, Robak, T, Ghia, P, Kahl, BS, Walker, P, Janowski, W, Simpson, D, Shadman, M, Ganly, PS, Laurenti, L, Opat, S, Tani, M, Ciepluch, H, Verner, E, Šimkovič, M, Österborg, A, Trněný, M, Tedeschi, A, Paik, JC, Kuwahara, SB, Feng, S, Ramakrishnan, V, Cohen, A, Huang, J, Hillmen, P, Brown, JR, Tam, CS, Robak, T, Ghia, P, Kahl, BS, Walker, P, Janowski, W, Simpson, D, Shadman, M, Ganly, PS, Laurenti, L, Opat, S, Tani, M, Ciepluch, H, Verner, E, Šimkovič, M, Österborg, A, Trněný, M, Tedeschi, A, Paik, JC, Kuwahara, SB, Feng, S, Ramakrishnan, V, Cohen, A, Huang, J, Hillmen, P, and Brown, JR
- Abstract
Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma whose tumors carry deletion of chromosome 17p13.1 [del(17p)] have an unfavorable prognosis and respond poorly to standard chemoimmunotherapy. Zanubrutinib is a selective next-generation Bruton tyrosine kinase inhibitor. We evaluated the safety and efficacy of zanubrutinib 160 mg twice daily in treatment-naïve patients with del(17p) disease enrolled in a dedicated, nonrandomized cohort (Arm C) of the phase 3 SEQUOIA trial. A total of 109 patients (median age, 70 years; range, 42 – 86) with centrally confirmed del(17p) were enrolled and treated. After a median of 18.2 months (range, 5.0 – 26.3), seven patients had discontinued study treatment due to progressive disease, four due to an adverse event, and one due to withdrawal of consent. The overall response rate was 94.5% with 3.7% of patients achieving complete response with or without incomplete hematologic recovery. The estimated 18-month progression-free survival rate was 88.6% (95% CI, 79.0 – 94.0) and the estimated 18-month overall survival rate was 95.1% (95% CI, 88.4 – 98.0). Most common all-grade adverse events included contusion (20.2%), upper respiratory tract infection (19.3%), neutropenia/neutrophil count decreased (17.4%), and diarrhea (16.5%). Grade ≥ 3 adverse events were reported in 53 patients (48.6%), most commonly neutropenia (12.9%) and pneumonia (3.7%). An adverse event of atrial fibrillation was reported in three patients (2.8%). Zanubrutinib was active and well tolerated in this large, prospectively enrolled treatment cohort of previously untreated patients with del(17p) chronic lymphocytic leukemia/small lymphocytic lymphoma. This trial was registered at ClinicalTrials.gov as #NCT03336333.
- Published
- 2020
9. An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma.
- Author
-
Hus, I, Dmoszynska, A, Manko, J, Hus, M, Jawniak, D, Soroka-Wojtaszko, M, Hellmann, A, Ciepluch, H, Skotnicki, A, Wolska-Smolen, T, Sulek, K, Robak, T, Konopka, L, and Kloczko, J
- Subjects
MULTIPLE myeloma ,SERUM ,BLOOD plasma ,PLASMACYTOMA ,THALIDOMIDE ,PIPERIDINE ,MULTIPLE myeloma diagnosis ,SURVIVAL ,ALBUMINS ,PREDICTIVE tests ,BLOOD proteins ,HEMOGLOBINS ,TIME ,CANCER relapse ,PROGNOSIS ,TREATMENT effectiveness ,IMMUNOSUPPRESSIVE agents ,GLOBULINS ,DRUG resistance in cancer cells - Abstract
The aim of this study was to assess the prognostic value of pretreatment clinical and laboratory parameters in refractory or relapsed multiple myeloma (MM) patients who have a long-term response to thalidomide (THAL), lasting at least 18 months. The study was carried out on 234 patients who received THAL for relapsed/refractory myeloma. Out of the 234 patients, 129 patients (55.1%) responded to THAL with a mean response duration of 11.9 months (ranging from 1 to 48) and an overall survival rate of 20.3 months (ranging 1-55 months). In 64 patients (27.4% of the whole group), the response to THAL lasted > or =18 months with a mean response lasting 24 months. Statistical analysis of the group of nonresponders and patients with long-term response to THAL showed a significantly higher serum albumin level (P=0.0003) and haemoglobin level (P=0.05), as well as a lower beta2 microglobulin (beta2M) (P=0.022), LDH (P=0.045) serum level in patients with long-term response. In this study, the LDH and serum albumin level were predictors for response to THAL therapy. The beta2M serum level was not a predictor for response to THAL. The albumin serum level was the best parameter distinguishing the group of patients with long-term response to THAL from the entire responding group (P=0.02). [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
10. Salvage therapy with thalidomide in refractory and relapsed multiple myeloma patients prior to peripherial stem cells transplantation
- Author
-
Dmoszynska, A., Hus, M., Grza̧śko, N., Jawniak, D., Wojciech Maciej Legiec, Ciepluch, H., Knopińska, W., Hellmann, A., Soroka-Wojtaszko, M., and Mańko, J.
11. 2-chlorodeoxyadenosine treatment of patients with chronic lymphocytic leukaemia associated with autoimmune haemolysis
- Author
-
Zaucha, J. M., Kazimierz Halaburda, Ciepluch, H., and Hellmann, A.
12. Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial.
- Author
-
Tam C.S., Robak T., Ghia P., Kahl B.S., Walker P., Janowski W., Simpson D., Shadman M., Ganly P.S., Laurenti L., Opat S., Tani M., Ciepluch H., Verner E., Simkovic M., Osterborg A., Trneny M., Tedeschi A., Paik J., Marimpietri C., Feng S., Huang J., Hillmen P., Brown J.R., Tam C.S., Robak T., Ghia P., Kahl B.S., Walker P., Janowski W., Simpson D., Shadman M., Ganly P.S., Laurenti L., Opat S., Tani M., Ciepluch H., Verner E., Simkovic M., Osterborg A., Trneny M., Tedeschi A., Paik J., Marimpietri C., Feng S., Huang J., Hillmen P., and Brown J.R.
- Abstract
Background: Patients with CLL/SLL whose tumor exhibits the deletion of chromosome 17p13.1 [del(17p)] have an unfavorable prognosis and respond poorly to standard chemoimmunotherapy. Several new options targeting B-cell receptor signaling have emerged as potential effective therapies in this high-risk group. Zanubrutinib (BGB-3111) is an investigational, next-generation Bruton tyrosine kinase (BTK) inhibitor, designed to maximize BTK occupancy and minimize off-target inhibition of TEC- and EGFR-family kinases. It has been shown to be highly potent, selective, and bioavailable with potentially advantageous pharmacokinetic and pharmacodynamic properties. In an early phase study, zanubrutinib demonstrated complete and sustained BTK occupancy in both peripheral blood mononuclear cells and lymph nodes and has been associated with durable clinical responses in patients with CLL/SLL (Tam, Blood 2019). Here, we present safety and efficacy data in treatment-naive (TN) patients with del(17p) CLL/SLL who are enrolled in the non-randomized Arm C of the SEQUOIA (BGB-3111-304) trial. Method(s): The SEQUOIA trial is an open-label, global, multicenter, phase 3 study that includes a non-randomized cohort (Arm C) of TN patients with del(17p) CLL/SLL treated with zanubrutinib (160 mg twice daily). Adult patients with CLL/SLL who met iwCLL criteria for treatment (Hallek, Blood 2008) were eligible if they were either >= 65 y of age or unsuitable for treatment with fludarabine, cyclophosphamide, and rituximab. Use of long-term anticoagulation was permitted. Central verification of del(17p) by fluorescence in situ hybridization with a minimum of 7% aberrant nuclei present was required for entry into Arm C. Response assessment was evaluated by investigator for CLL per modified iwCLL criteria (Hallek, Blood 2008; Cheson, J Clin Oncol 2012) and for SLL per Lugano criteria (Cheson, J Clin Oncol 2014). Result(s): In total, 109 patients with centrally confirmed del(17p) were enrolled into Arm C
13. Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial.
- Author
-
Brown J.R., Robak T., Ghia P., Kahl B.S., Walker P., Janowski W., Chan H., Shadman M., Ganly P.S., Laurenti L., Opat S., Tani M., Ciepluch H., Verner E., Simkovic M., Osterborg A., Trneny M., Tedeschi A., Blombery P., Paik J.C., Yin F., Feng S., Ramakrishnan V., Huang J., Hillmen P., Tam C.S., Brown J.R., Robak T., Ghia P., Kahl B.S., Walker P., Janowski W., Chan H., Shadman M., Ganly P.S., Laurenti L., Opat S., Tani M., Ciepluch H., Verner E., Simkovic M., Osterborg A., Trneny M., Tedeschi A., Blombery P., Paik J.C., Yin F., Feng S., Ramakrishnan V., Huang J., Hillmen P., and Tam C.S.
- Abstract
Background: Patients (pts) with CLL/SLL whose tumor exhibits the deletion of chromosome 17p13.1 [del(17p)] have an unfavorable prognosis and respond poorly to standard chemoimmunotherapy. Zanubrutinib (BGB-3111) is an investigational, next-generation Bruton tyrosine kinase (BTK) inhibitor. In the ASPEN study of pts with Waldenstrom macroglobulinemia, zanubrutinib was associated with important safety advantages compared to ibrutinib, especially regarding cardiovascular toxicity (Blood; in press). The initial results from Arm C of the SEQUOIA (BGB-3111-304) trial of zanubrutinib in a large cohort of TN CLL/SLL pts with del(17p) were recently presented with a median follow-up of 10 months (Blood 2019;134:851). Presented here is an updated analysis for safety and efficacy in this cohort. Method(s): The SEQUOIA trial (NCT03336333) is an open-label, global, multicenter, phase 3 study that includes a nonrandomized cohort (Arm C) of TN pts with del(17p) CLL/SLL treated with zanubrutinib (160 mg twice daily). Adult pts with CLL/SLL who met International Workshop on CLL (iwCLL) criteria for treatment (Blood 2008;111:5446) were eligible if they were aged >=65 y or unsuitable for treatment with fludarabine, cyclophosphamide, and rituximab. Use of long-term anticoagulation was permitted. Central verification of del(17p) by fluorescence in situ hybridization with a minimum of 7% aberrant nuclei present was required for entry into Arm C. Response was evaluated by investigator for CLL...Copyright © 2020 American Society of Hematology
14. Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial.
- Author
-
Tam C.S., Robak T., Ghia P., Kahl B.S., Walker P., Janowski W., Simpson D., Shadman M., Ganly P.S., Laurenti L., Opat S., Tani M., Ciepluch H., Verner E., Simkovic M., Osterborg A., Trneny M., Tedeschi A., Paik J., Marimpietri C., Feng S., Huang J., Hillmen P., Brown J.R., Tam C.S., Robak T., Ghia P., Kahl B.S., Walker P., Janowski W., Simpson D., Shadman M., Ganly P.S., Laurenti L., Opat S., Tani M., Ciepluch H., Verner E., Simkovic M., Osterborg A., Trneny M., Tedeschi A., Paik J., Marimpietri C., Feng S., Huang J., Hillmen P., and Brown J.R.
- Abstract
Background: Patients with CLL/SLL whose tumor exhibits the deletion of chromosome 17p13.1 [del(17p)] have an unfavorable prognosis and respond poorly to standard chemoimmunotherapy. Several new options targeting B-cell receptor signaling have emerged as potential effective therapies in this high-risk group. Zanubrutinib (BGB-3111) is an investigational, next-generation Bruton tyrosine kinase (BTK) inhibitor, designed to maximize BTK occupancy and minimize off-target inhibition of TEC- and EGFR-family kinases. It has been shown to be highly potent, selective, and bioavailable with potentially advantageous pharmacokinetic and pharmacodynamic properties. In an early phase study, zanubrutinib demonstrated complete and sustained BTK occupancy in both peripheral blood mononuclear cells and lymph nodes and has been associated with durable clinical responses in patients with CLL/SLL (Tam, Blood 2019). Here, we present safety and efficacy data in treatment-naive (TN) patients with del(17p) CLL/SLL who are enrolled in the non-randomized Arm C of the SEQUOIA (BGB-3111-304) trial. Method(s): The SEQUOIA trial is an open-label, global, multicenter, phase 3 study that includes a non-randomized cohort (Arm C) of TN patients with del(17p) CLL/SLL treated with zanubrutinib (160 mg twice daily). Adult patients with CLL/SLL who met iwCLL criteria for treatment (Hallek, Blood 2008) were eligible if they were either >= 65 y of age or unsuitable for treatment with fludarabine, cyclophosphamide, and rituximab. Use of long-term anticoagulation was permitted. Central verification of del(17p) by fluorescence in situ hybridization with a minimum of 7% aberrant nuclei present was required for entry into Arm C. Response assessment was evaluated by investigator for CLL per modified iwCLL criteria (Hallek, Blood 2008; Cheson, J Clin Oncol 2012) and for SLL per Lugano criteria (Cheson, J Clin Oncol 2014). Result(s): In total, 109 patients with centrally confirmed del(17p) were enrolled into Arm C
15. Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial.
- Author
-
Brown J.R., Robak T., Ghia P., Kahl B.S., Walker P., Janowski W., Chan H., Shadman M., Ganly P.S., Laurenti L., Opat S., Tani M., Ciepluch H., Verner E., Simkovic M., Osterborg A., Trneny M., Tedeschi A., Blombery P., Paik J.C., Yin F., Feng S., Ramakrishnan V., Huang J., Hillmen P., Tam C.S., Brown J.R., Robak T., Ghia P., Kahl B.S., Walker P., Janowski W., Chan H., Shadman M., Ganly P.S., Laurenti L., Opat S., Tani M., Ciepluch H., Verner E., Simkovic M., Osterborg A., Trneny M., Tedeschi A., Blombery P., Paik J.C., Yin F., Feng S., Ramakrishnan V., Huang J., Hillmen P., and Tam C.S.
- Abstract
Background: Patients (pts) with CLL/SLL whose tumor exhibits the deletion of chromosome 17p13.1 [del(17p)] have an unfavorable prognosis and respond poorly to standard chemoimmunotherapy. Zanubrutinib (BGB-3111) is an investigational, next-generation Bruton tyrosine kinase (BTK) inhibitor. In the ASPEN study of pts with Waldenstrom macroglobulinemia, zanubrutinib was associated with important safety advantages compared to ibrutinib, especially regarding cardiovascular toxicity (Blood; in press). The initial results from Arm C of the SEQUOIA (BGB-3111-304) trial of zanubrutinib in a large cohort of TN CLL/SLL pts with del(17p) were recently presented with a median follow-up of 10 months (Blood 2019;134:851). Presented here is an updated analysis for safety and efficacy in this cohort. Method(s): The SEQUOIA trial (NCT03336333) is an open-label, global, multicenter, phase 3 study that includes a nonrandomized cohort (Arm C) of TN pts with del(17p) CLL/SLL treated with zanubrutinib (160 mg twice daily). Adult pts with CLL/SLL who met International Workshop on CLL (iwCLL) criteria for treatment (Blood 2008;111:5446) were eligible if they were aged >=65 y or unsuitable for treatment with fludarabine, cyclophosphamide, and rituximab. Use of long-term anticoagulation was permitted. Central verification of del(17p) by fluorescence in situ hybridization with a minimum of 7% aberrant nuclei present was required for entry into Arm C. Response was evaluated by investigator for CLL...Copyright © 2020 American Society of Hematology
16. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
- Author
-
Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, Šimkovič M, Shadman M, Österborg A, Laurenti L, Walker P, Opat S, Chan H, Ciepluch H, Greil R, Tani M, Trněný M, Brander DM, Flinn IW, Grosicki S, Verner E, Tedeschi A, Li J, Tian T, Zhou L, Marimpietri C, Paik JC, Cohen A, Huang J, Robak T, and Hillmen P
- Subjects
- Antineoplastic Combined Chemotherapy Protocols adverse effects, Bendamustine Hydrochloride, Humans, Piperidines, Pyrazoles, Pyrimidines, Rituximab, COVID-19, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Sequoia
- Abstract
Background: Zanubrutinib is a next-generation, selective Bruton tyrosine kinase inhibitor with efficacy in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). We compared zanubrutinib with bendamustine-rituximab to determine its effectiveness as frontline therapy in patients with CLL or SLL., Methods: We conducted an open-label, multicentre, phase 3 study at 153 academic or community hospitals in 14 countries and regions. Eligible patients had untreated CLL or SLL requiring treatment as per International Workshop on CLL criteria; were aged 65 years or older, or 18 years or older and had comorbidities; and had an Eastern Cooperative Oncology Group performance status score of 0-2. A central interactive web response system randomly assigned patients without del(17)(p13·1) to zanubrutinib (group A) or bendamustine-rituximab (group B) by sequential block method (permutated blocks with a random block size of four). Patients with del(17)(p13·1) were enrolled in group C and received zanubrutinib. Zanubrutinib was administered orally at 160 mg twice per day (28-day cycles); bendamustine at 90 mg/m
2 of body surface area on days 1 and 2 for six cycles plus rituximab at 375 mg/m2 of body surface area the day before or on day 1 of cycle 1, and 500 mg/m2 of body surface area on day 1 of cycles 2-6, were administered intravenously. The primary endpoint was progression-free survival per independent review committee in the intention-to-treat population in groups A and B, with minimum two-sided α of 0·05 for superiority. Safety was analysed in all patients who received at least one dose of study treatment. The study is registered with ClinicalTrials.gov, NCT03336333, and is closed to recruitment., Findings: Between Oct 31, 2017, and July 22, 2019, 590 patients were enrolled; patients without del(17)(p13·1) were randomly assigned to zanubrutinib (group A; n=241) or bendamustine-rituximab (group B; n=238). At median follow-up of 26·2 months (IQR 23·7-29·6), median progression-free survival per independent review committee was not reached in either group (group A 95% CI not estimable [NE] to NE; group B 28·1 months to NE). Progression-free survival was significantly improved in group A versus group B (HR 0·42 [95% CI 0·28 to 0·63]; two-sided p<0·0001). The most common grade 3 or worse adverse event was neutropenia (27 [11%] of 240 patients in group A, 116 [51%] of 227 in group B, and 17 [15%] of 111 patients in group C). Serious adverse events occurred in 88 (37%) of 240 patients in group A, 113 (50%) of 227 patients in group B, and 45 (41%) of 111 patients in group C. Adverse events leading to death occurred in 11 (5%) of 240 patients in group A, 12 (5%) of 227 patients in group B, and three (3%) of 111 patients in group C, most commonly due to COVID-19 (four [2%] of 240 patients in group A), diarrhoea, and aspiration pneumonia (two each [1%] of 227 patients in group B)., Interpretation: Zanubrutinib significantly improved progression-free survival versus bendamustine-rituximab, with an acceptable safety profile consistent with previous studies. These data support zanubrutinib as a potential new treatment option for untreated CLL and SLL., Funding: BeiGene., Competing Interests: Declaration of interests CST reports receiving funding from AbbVie and Janssen; and honoraria from AbbVie, BeiGene, Janssen, Novartis, and Roche, outside the submitted work. JRB reports receiving funding from Gilead, Lilly–LOXO, TG Therapeutics, Verastem–SecuraBio, and Sun; consulting fees from AbbVie, Acerta–AstraZeneca, BeiGene, Bristol Myers Squibb–Juno–Celgene, Catapult Therapeutics, Dynamo Therapeutics, Eli Lilly, Genentech/Roche, Gilead, Janssen, Kite, LOXO, MEI Pharma, MorphoSys, Nextcea, Novartis, Octapharma, Pfizer, Pharmacyclics, Rigel, Sunesis, TG Therapeutics, and Verastem; honoraria from Janssen; and participation on an advisory board for Invectys and MorphoSys, outside of the submitted work. BSK reports receiving funding from BeiGene paid to Washington University School of Medicine (St Louis, MO, USA), and receiving consulting fees from AbbVie, AstraZeneca, BeiGene, Janssen, and Pharmacyclics, outside the submitted work. PG reports receiving funding from BeiGene with regards to the submitted work; funding from AbbVie, AstraZeneca, Janssen, Gilead, Novartis, and Sunesis; consulting fees from and participating on an advisory board for AbbVie, AstraZeneca, ArQule–MSD, Celgene–Juno–Bristol Myers Squibb, Janssen, Lilly–LOXO, and Roche; and receiving honoraria from AbbVie, AstraZeneca, Janssen, and MSD, outside the submitted work. KG reports receiving consulting fees and honoraria from BeiGene, with regards to the submitted work; funding from AbbVie, Amgen, AstraZeneca, Janssen, Novartis, Roche, Sanofi-Genzyme, and Takeda and paid to the Next Generation Hematology Association; receiving consulting fees from GSK and Sandoz; receiving honoraria from AbbVie, Amgen, AstraZeneca, BeiGene, Gilead, GSK, Janssen, Karyopharm, Novartis, Pfizer, Roche, Sandoz, Takeda, and Teva; receiving financial support for attending meetings or travel, or both, from Janssen, Roche, and Sanofi-Genzyme; participating on an advisory board for AbbVie, Amgen, AstraZeneca, Gilead, GSK, Janssen, Novartis, Roche, Sandoz, and Takeda; and a leadership role at the Next Generation Hematology Association, outside the submitted work. WJ reports receiving funding from BeiGene and Janssen, with regards to the submitted work, and funding from AstraZeneca and TG Therapeutics, outside the submitted work. MŠ reports receiving consulting fees from AbbVie and AstraZeneca; receiving honoraria from AbbVie and Janssen-Cilag; participating on an advisory board for AbbVie, AstraZeneca, and Janssen-Cilag; and stock or stock options, or both, from AbbVie, AstraZeneca, Eli Lilly, Johnson & Johnson, and Merck, outside the submitted work. MS reports receiving funding from BeiGene paid to Fred Hutchinson Cancer Research Center and the University of Washington (Seattle, WA, USA), with regards to the submitted work; funding from AbbVie, AstraZeneca, Atara Biotherapeutics, BeiGene, GenMab, Genentech, Gilead, Mustang Bio, Bristol Myers Squibb, Celgene, Pharmacyclics, Sunesis, and TG Therapeutics; and receiving consulting fees from AbbVie, Adaptimmune, Adaptive Biotechnologies, AstraZeneca, Atara Biotherapeutics, BeiGene, Bristol Myers Squibb, Eli Lilly, Epizyme, Genentech, InnatePharma, Kite Pharma, MorphoSys, Mustang Bio, Pharmacyclics, Sound Biologics, and TG Therapeutics, outside the submitted work. PW reports receiving consulting fees from Acerta and BeiGene, outside the submitted work. SO reports receiving funding from BeiGene paid to Monash University (Clayton, VIC, Australia), with regards to the submitted work; and honoraria and participating on an advisory board for BeiGene, outside the submitted work. HCh reports receiving financial support for attending meetings or travel, or both, from Celgene and Janssen, and participating on an advisory board for AbbVie, Eusa, and Janssen, outside the submitted work. RG reports receiving consulting fees from AbbVie, AstraZeneca, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Janssen, Merck, MSD, Novartis, Roche, and Takeda; honoraria from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Merck, MSD, Novartis, Roche, Takeda, and Sandoz; financial support for attending meetings or travel, or both, from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Janssen, MSD, Novartis, and Roche; and participating on an advisory board for AbbVie, AstraZeneca, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Janssen, Merck, MSD, Novartis, Roche, and Takeda, outside the submitted work. MTr reports receiving consulting fees from AbbVie, Amgen, Janssen, Bristol Myers Squibb, Gilead Sciences, Incyte, MorphoSys, Novartis, Roche, Takeda; receiving honoraria from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Gilead Sciences, Incyte, Janssen, Roche, MorphoSys, Novartis, Portolla, and Takeda; receiving financial support for attending meetings or travel, or both, from AbbVie, Bristol Myers Squibb, Gilead, Janssen, Roche, and Takeda; participating on an advisory board for AbbVie, Bristol Myers Squibb, Incyte, Janssen, MorphoSys, Novartis, Portolla, Roche, and Takeda; and employment at Charles University General Hospital in Prague, outside the submitted work. DMB reports receiving funding from AbbVie, ArQule, Ascentage, AstraZeneca, BeiGene, DTRM, Genetech, Juno–Celgene–Bristol Myers Squibb, LOXO, MEI Pharma, Novaris, Pharmacyclics, and TG Therapeutics; receiving consulting fees from AbbVie, Genentech, Pharmacyclics, Pfizer, TG Therapeutics, and Verastem; participating on an advisory board for AbbVie, Genentech, Novartis, Pharmacyclics, Pfizer, TG Therapeutics, and Verastem; and a leadership role with NCCN (panel member), informCLL registry (steering committee; AbbVie), and Biosimilars outcomes research panel (Pfizer), outside the submitted work. IWF reports receiving funding from AbbVie, Acerta Pharma, Agios, ArQule, AstraZeneca, BeiGene, Calithera Biosciences, Celgene, Constellation Pharmaceuticals, Curis, Forma Therapeutics, Forty Seven, Genentech, Gilead Sciences, IGM Biosciences, Incyte, Infinity Pharmaceuticals, Janssen, Juno Therapeutics, Karyopharm Therapeutics, Kite Pharma, LOXO, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, Portola Pharmaceuticals, Rhizen Pharmaceuticals, Roche, Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium Therapeutics, Triphase Research & Development, Unum Therapeutics, and Verastem, paid to the Sarah Cannon Research Institute; and consulting fees from AbbVie, AstraZeneca, BeiGene, Century Therapeutics, Genentech, Gilead Sciences, Great Point Partners, Hutchison MediPharma, Iksuda Therapeutics, Janssen, Juno Therapeutics, Kite Pharma, MorphoSys, Novartis, Nurix Therapeutics, Pharmacyclics, Roche, Seattle Genetics, Servier Pharmaceuticals, Takeda, TG Therapeutics, Unum Therapeutics, Verastem, Vincerx Pharma, and Yingli Pharmaceuticals, paid to the Sarah Cannon Research Institute, outside the submitted work. AT reports receiving consulting fees from AbbVie, AstraZeneca, BeiGene, and Janssen; and honoraria from AbbVie, AstraZeneca, BeiGene, and Janssen, outside the submitted work. TT, LZ, CM, JCP, and AC are employees of BeiGene, with regards to the submitted work, and report stocks or stock options, or both, from BeiGene, outside the submitted work. JH is an employee of BeiGene, with regards to the submitted work; reports receiving royalties from BeiGene; receiving financial support for attending meetings or travel, or both, from BeiGene and Protara; patents with BeiGene; a leadership role with BeiGene and Protara; and stock or stock options, or both, from BeiGene and Protara, outside the submitted work. TR reports receiving funding from BeiGene, with regards to the submitted work; receiving funding from AbbVie, AstraZeneca, Janssen, and Roche; and participating on an advisory board for AbbVie, AstraZeneca, BeiGene, Janssen, and Roche. PH reports receiving funding from AbbVie, Gilead, Janssen, Pharmacyclics, and Roche; honoraria from AbbVie, AstraZeneca, BeiGene, Janssen, Pharmacyclics, and SOBI; and financial support for attending meetings or travel, or both, from AbbVie and Janssen, outside the submitted work. All other authors declare no competing interests., (Copyright © 2022 Elsevier Ltd. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
17. Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion
- Author
-
Tam CS, Robak T, Ghia P, Kahl BS, Walker P, Janowski W, Simpson D, Shadman M, Ganly PS, Laurenti L, Opat S, Tani M, Ciepluch H, Verner E, Šimkovič M, Österborg A, Trněný M, Tedeschi A, Paik JC, Kuwahara SB, Feng S, Ramakrishnan V, Cohen A, Huang J, Hillmen P, and Brown JR
- Subjects
- Aged, Humans, Piperidines, Pyrazoles, Pyrimidines adverse effects, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell genetics
- Abstract
Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma whose tumors carry deletion of chromosome 17p13.1 [del(17p)] have an unfavorable prognosis and respond poorly to standard chemoimmunotherapy. Zanubrutinib is a selective next-generation Bruton tyrosine kinase inhibitor. We evaluated the safety and efficacy of zanubrutinib 160 mg twice daily in treatment-naïve patients with del(17p) disease enrolled in a dedicated, nonrandomized cohort (Arm C) of the phase 3 SEQUOIA trial. A total of 109 patients (median age, 70 years; range, 42 - 86) with centrally confirmed del(17p) were enrolled and treated. After a median of 18.2 months (range, 5.0 - 26.3), seven patients had discontinued study treatment due to progressive disease, four due to an adverse event, and one due to withdrawal of consent. The overall response rate was 94.5% with 3.7% of patients achieving complete response with or without incomplete hematologic recovery. The estimated 18-month progression-free survival rate was 88.6% (95% CI, 79.0 - 94.0) and the estimated 18-month overall survival rate was 95.1% (95% CI, 88.4 - 98.0). Most common all-grade adverse events included contusion (20.2%), upper respiratory tract infection (19.3%), neutropenia/neutrophil count decreased (17.4%), and diarrhea (16.5%). Grade ≥ 3 adverse events were reported in 53 patients (48.6%), most commonly neutropenia (12.9%) and pneumonia (3.7%). An adverse event of atrial fibrillation was reported in three patients (2.8%). Zanubrutinib was active and well tolerated in this large, prospectively enrolled treatment cohort of previously untreated patients with del(17p) chronic lymphocytic leukemia/small lymphocytic lymphoma. This trial was registered at ClinicalTrials.gov as #NCT03336333.
- Published
- 2021
- Full Text
- View/download PDF
18. Modulation of the activity of calcium-activated neutral proteases (calpains) in chronic lymphocytic leukemia (B-CLL) cells.
- Author
-
Witkowski JM, Zmuda-Trzebiatowska E, Swiercz JM, Cichorek M, Ciepluch H, Lewandowski K, Bryl E, and Hellmann A
- Subjects
- Adult, Aged, Aged, 80 and over, Apoptosis, CD3 Complex, Calcium metabolism, Enzyme Activation, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Male, Middle Aged, Calpain metabolism, Leukemia, Lymphocytic, Chronic, B-Cell enzymology, Signal Transduction
- Abstract
Decreased susceptibility to apoptosis and impaired proliferative control are thought to be responsible for prolonged life span and accumulation of chronic lymphocytic leukemia (B-CLL) cells. The activity of calpains (calcium-dependent, neutral proteases, active in the cells responding to signals inducing a rise of cytoplasmic Ca(++)) is involved in the regulation of apoptosis of some cell types by interaction with caspase-3. This work verifies the hypothesis of the abnormal activity of calpains and its role in reduced apoptosis of the B-CLL cells. Casein zymography, reverse transcriptase-polymerase chain reaction, and Western blotting were used for identification and quantification of the activity and expression of calpains in B-CLL cells and purified normal B lymphocytes. The activity and expression of mu-calpain (requiring micromolar Ca(++) for activation) are significantly higher in the leukemic than in nonmalignant cells. Contrarily, the activity and expression of m-calpain (requiring millimolar Ca(++)) as well as the expression of calpastatin (an endogenous inhibitor of calpains) are unchanged or reduced in the B-CLL lymphocytes. Correspondingly, the activity of caspase-3 is many times lower in the B-CLL cells than in normal B lymphocytes. Inhibition of overexpressed mu-calpain in living B-CLL cells in vitro results in doubling of the proportion of the cells undergoing spontaneous apoptosis. This observation suggests a possible role for calpains in longer survival of the B-CLL cells and may open new therapeutic possibilities.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.